Literature DB >> 14701735

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Bernd B Zeisig1, Tom Milne, María-Paz García-Cuéllar, Silke Schreiner, Mary-Ellen Martin, Uta Fuchs, Arndt Borkhardt, Sumit K Chanda, John Walker, Richard Soden, Jay L Hess, Robert K Slany.   

Abstract

MLL fusion proteins are oncogenic transcription factors that are associated with aggressive lymphoid and myeloid leukemias. We constructed an inducible MLL fusion, MLL-ENL-ERtm, that rendered the transcriptional and transforming properties of MLL-ENL strictly dependent on the presence of 4-hydroxy-tamoxifen. MLL-ENL-ERtm-immortalized hematopoietic cells required 4-hydroxy-tamoxifen for continuous growth and differentiated terminally upon tamoxifen withdrawal. Microarray analysis performed on these conditionally transformed cells revealed Hoxa9 and Hoxa7 as well as the Hox coregulators Meis1 and Pbx3 among the targets upregulated by MLL-ENL-ERtm. Overexpression of the Hox repressor Bmi-1 inhibited the growth-transforming activity of MLL-ENL. Moreover, the enforced expression of Hoxa9 in combination with Meis1 was sufficient to substitute for MLL-ENL-ERtm function and to maintain a state of continuous proliferation and differentiation arrest. These results suggest that MLL fusion proteins impose a reversible block on myeloid differentiation through aberrant activation of a limited set of homeobox genes and Hox coregulators that are consistently expressed in MLL-associated leukemias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14701735      PMCID: PMC343796          DOI: 10.1128/MCB.24.2.617-628.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.

Authors:  Marco Birke; Silke Schreiner; María-Paz García-Cuéllar; Kerstin Mahr; Fritz Titgemeyer; Robert K Slany
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Core-binding factors in haematopoiesis and leukaemia.

Authors:  Nancy A Speck; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Authors:  S Ziemin-van der Poel; N R McCabe; H J Gill; R Espinosa; Y Patel; A Harden; P Rubinelli; S D Smith; M M LeBeau; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

4.  The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.

Authors:  Jorge F DiMartino; Paul M Ayton; Everett H Chen; Clarissa C Naftzger; Bryan D Young; Michael L Cleary
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

Review 5.  The role of MLL in hematopoiesis and leukemia.

Authors:  Patricia Ernst; Jing Wang; Stanley J Korsmeyer
Journal:  Curr Opin Hematol       Date:  2002-07       Impact factor: 3.284

Review 6.  Translocations of the RARalpha gene in acute promyelocytic leukemia.

Authors:  A Zelent; F Guidez; A Melnick; S Waxman; J D Licht
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

Review 7.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

9.  Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.

Authors:  Katherine R Calvo; David B Sykes; Martina P Pasillas; Mark P Kamps
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

10.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  160 in total

Review 1.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.

Authors:  Ali Shilatifard
Journal:  Annu Rev Biochem       Date:  2012       Impact factor: 23.643

2.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

3.  Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation.

Authors:  Mi Cai; Ellen M Langer; Jennifer G Gill; Ansuman T Satpathy; Jörn C Albring; Wumesh KC; Theresa L Murphy; Kenneth M Murphy
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

4.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

5.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

6.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

7.  Interaction of MLL amino terminal sequences with menin is required for transformation.

Authors:  Corrado Caslini; Zhaohai Yang; Mohamad El-Osta; Thomas A Milne; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

8.  Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes.

Authors:  Jill S Butler; Cecilia I Zurita-Lopez; Steven G Clarke; Mark T Bedford; Sharon Y R Dent
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 9.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

10.  HOX expression patterns identify a common signature for favorable AML.

Authors:  M Andreeff; V Ruvolo; S Gadgil; C Zeng; K Coombes; W Chen; S Kornblau; A E Barón; H A Drabkin
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.